Reports Q2 revenue $0.5M, consensus $740K. “As we approach the August 14 PDUFA date, the Company has been preparing for the commercialization of HEPZATO KIT, if approved,” said Gerard Michel, CEO. “As part of this preparation, we continue to add experienced personnel across the key functional areas involved in commercialization.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DCTH: